Formoterol

also known as formoterol fumarate · Foradil · Foradil Aerolizer · formoterol (fumarate dihydrate) · PT005 · Atimos · FOR · Oxis Turbuhaler · +19 more

Other / unclassified

Developed for: asthma · chronic obstructive pulmonary disease · childhood onset asthma · chronic asthma · cough variant asthma · COVID-19 · exercise-induced bronchoconstriction · pulmonary emphysema
+15 more
· adult acute respiratory distress syndrome · bronchiectasis · chronic bronchitis · diabetic kidney disease · idiopathic pulmonary fibrosis · long COVID-19 · lung disorder · obesity disorder · obstructive lung disease · type 1 diabetes mellitus · type 2 diabetes mellitus · acute asthma · acute respiratory failure · Alzheimer disease · pneumonia
Investigated by: AstraZeneca · Chiesi Farmaceutici S.p.A. · Pearl Therapeutics, Inc. · Dey · Organon and Co · Novartis
+128 more
· Orion Corporation, Orion Pharma · Mundipharma Research Limited · Parexel · Eurofarma Laboratorios S.A. · GlaxoSmithKline · Novartis Pharmaceuticals · SkyePharma AG · Zhujiang Hospital · Abbott · Boehringer Ingelheim · University Hospital, Antwerp · Università degli Studi di Ferrara · Ache Laboratorios Farmaceuticos S.A. · Assistance Publique - Hôpitaux de Paris · Brigham and Women's Hospital · China-Japan Friendship Hospital · Hull University Teaching Hospitals NHS Trust · Morten Hostrup, PhD · Schering-Plough · Shenzhen People's Hospital · Tongji Hospital · University Hospital, Lille · Zambon SpA · Zunyi Medical College · Alkermes, Inc. · Alpha Bioresearch S.L. · Beijing Chao Yang Hospital · Beth Israel Deaconess Medical Center · Bispebjerg Hospital · Boston Children's Hospital · Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS · British Columbia Cancer Agency · Bugra Kerget · CISCRP · Central South University · Centre Hospitalier Intercommunal Creteil · Centre Hospitalier Universitaire, Amiens · Chongqing Songshan Hospital · Cipla Ltd. · ClinResearch, GmbH · Cognizant Technology Solution · Columbia University · Corporate Translations Inc · Dey, L.P. · Dialysis Clinic, Inc. · Dynamic Solutions · Esteve · Fasa University of Medical Sciences · Federal State Budgetary Institution, Pulmonology Scientific Research Institute · First Hospital of China Medical University · Fondazione Salvatore Maugeri · Guangdong Provincial Hospital of Traditional Chinese Medicine · Hat Yai Medical Education Center · Henan Provincial People's Hospital · Henan University of Traditional Chinese Medicine · Hormone Laboratory, Aker University Hospital, Oslo, Norway · Hospital General de Requena · Huashan Hospital · IQVIA Pty Ltd · Imperial College London · Inner Mongolia People's Hospital · Integrated Therapeutics Group · Johannes Gutenberg University Mainz · KU Leuven · Kaohsiung Chest Disease Prevention and Health Education Association · Kindeva Drug Delivery · Laval University · MDS Pharma Services · MEDA Pharma GmbH & Co. KG · Mahidol University · Mayo Clinic · McGill University Health Centre/Research Institute of the McGill University Health Centre · Medical University of Lodz · Medical University of South Carolina · all 134 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed asthma 2 milestones
Filed	UK (MHRA)	Bufomix Easyhaler	asthma	2016-02-02	“we have submitted a marketing authorisation application for the budesonide-formoterol combined formulation in Germany, the United Kingdom and France.” orionpharma.com ↗
Filed	EU (EMA)	—	asthma	2013-03-21	“Orion Corporation has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family in Europe.” orionpharma.com ↗ “LAS40464, the combination of aclidinium with formoterol which has been filed for registration in the EU” astrazeneca.com ↗
Approved Indication not stated 3 milestones
Approved	EU (EMA)	DuoResp Spiromax	—	2014-04-28	europa.eu ↗
Label expansion	US (FDA)	FORADIL	—	2003-06-27	fda.gov ↗
Approved	US (FDA)	FORADIL	—	2001-02-16	fda.gov ↗

Trials 265 · started per year

today

US approved 2001

EU approved 2014

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 126 trials · 1 missed
Phase 1	NCT07433569	Mar → Jun 2026	asthma	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06723756	Jan → Jun 2025	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT05898984	Apr → Jul 2023	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT05830071	Mar → Oct 2023	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT04600505	Oct 2020 → May 2021	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03906045	Apr 2019 → Mar 2020	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03859414	Mar → Jul 2019	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT03795350	Jan 2019 → Apr 2020	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Terminated	No outcome recorded
Phase 1	NCT03740373	Sep → Oct 2018	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT03311373	Oct → Dec 2017	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT03250182	Aug → Dec 2017	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT02975843	Nov 2016 → Mar 2017	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT02631941	Jan → Jul 2016	asthma	Zambon SpA	Completed	Mixed
Phase 1	NCT03073057	Jan → Mar 2016	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT02237508	Sep 2014 → Feb 2015	asthma	Zambon SpA	Completed	Missed primary
Phase 1	NCT02197975	Aug → Oct 2014	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT02196714	Jul → Sep 2014	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT02119234	Mar 2014 → Feb 2015	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1	NCT01423305	Aug → Oct 2011	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01386996	Jul → Nov 2011	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01181063	Aug → Oct 2010	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT00657774	Apr → Sep 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 1	NCT00569712	Jan 2007 → Dec 2008	lung cancer, precancerous condition	British Columbia Cancer Agency	Completed	No outcome recorded
Phase 1	NCT00418509	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00940329	Apr → Jul 2004	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT00280358	? → Dec 2005	—	Dey	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT06110403	Sep 2023 → Sep 2026 overdue	chronic obstructive pulmonary disease	University Hospital, Lille	Recruiting	No outcome recorded
Phase 1/2	NCT01176747	Aug → Sep 2010	asthma, chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 247 trials · 13 met primary
Phase 2	NCT07301736	Dec 2025 → Jun 2027 expected	asthma	Chiesi Farmaceutici S.p.A.	Recruiting	No outcome recorded
Phase 2	NCT07022418	Dec 2025 → Dec 2026 expected	diabetic kidney disease	Medical University of South Carolina	Recruiting	No outcome recorded
Phase 2	NCT04087590	Jan 2020 → Mar 2023	chronic obstructive pulmonary disease	University Hospital, Lille	Terminated	No outcome recorded
Phase 2	NCT03590379	Jun → Oct 2018	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	Met primary
Phase 2	NCT03276078	Nov 2017 → Jun 2018	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT03086460	Sep 2017 → Jul 2018	asthma	Chiesi Farmaceutici S.p.A.	Completed	Met primary
Phase 2	NCT03108534	Feb → Sep 2017	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT02787967	Aug 2016 → Jun 2017	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT02796651	Jun → Dec 2016	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 2	NCT02196077	Aug 2014 → Mar 2015	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT02148120	Apr → Oct 2014	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT02048644	Mar 2014 → Apr 2015	idiopathic pulmonary fibrosis	Hull University Teaching Hospitals NHS Trust	Completed	No outcome recorded
Phase 2	NCT01783821	Jul 2013 → Jul 2015	adult acute respiratory distress syndrome	Mayo Clinic	Completed	Met primary
Phase 2	NCT01615874	Jan → Sep 2013	asthma	Organon and Co	Withdrawn	No outcome recorded
Phase 2	NCT01738087	Nov 2012 → Jan 2013	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01641081	Jun 2012 → Feb 2013	asthma	AstraZeneca	Completed	Met primary
Phase 2	NCT01650441	Apr 2012 → Jun 2013	asthma	University Hospital, Antwerp	Completed	No outcome recorded
Phase 2	NCT01468272	Nov 2011 → Aug 2012	childhood onset asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01349816	Jun → Nov 2011	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	Met primary
Phase 2	NCT01349803	May → Nov 2011	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01349257	May → Jun 2011	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01256086	Dec 2010 → Jul 2011	asthma	MEDA Pharma GmbH & Co. KG	Completed	No outcome recorded
Phase 2	NCT01258803	Dec 2010 → Oct 2011	asthma	Organon and Co	Completed	Met primary
Phase 2	NCT01191424	Oct 2010 → Sep 2011	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01136655	Sep 2010 → Dec 2011	asthma	AstraZeneca	Completed	Met primary
Phase 2	NCT01168310	Aug 2010	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT01043601	Jul 2010 → Apr 2011	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT01113593	May 2010	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT01048333	Jan → May 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 2	NCT00801684	Feb → Apr 2009	chronic obstructive pulmonary disease	Alkermes, Inc.	Completed	Met primary
Phase 2	NCT00746330	Aug 2008 → Apr 2009	asthma	Novartis	Completed	No outcome recorded
Phase 2	NCT00624754	Mar 2008 → Jul 2012	obstructive lung disease	Assistance Publique - Hôpitaux de Paris	Completed	Met primary
Phase 2	NCT01343745	Feb → Aug 2008	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00635882	Feb 2008 → Jun 2009	asthma	Organon and Co	Completed	Met primary
Phase 2	NCT00626522	Feb → Nov 2008	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 2	NCT00443482	Feb → May 2007	asthma	Novartis	Completed	No outcome recorded
Phase 2	NCT00403286	Nov 2006 → May 2007	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00314509	Jul 2005 → Jan 2006	asthma	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00215371	Jul → Oct 2002	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT00215358	Jul → Oct 2002	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT02238119	Feb → Aug 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242240	Mar → Dec 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00239278	Jan 2001 → Jan 2005	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00215397	? → Feb 2003	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT00215384	? → Apr 2003	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00215423	? → Dec 2003	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00215410	? → Oct 2003	asthma	Dey	Completed	No outcome recorded

Phase 2/34 trials · 1 met primary
Phase 2/3	NCT04331470	Apr 2020	COVID-19	Fasa University of Medical Sciences	Unknown	No outcome recorded
Phase 2/3	NCT02693769	Jul → Oct 2016	asthma	Mundipharma Research Limited	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT02195375	Sep 2014 → May 2016	chronic obstructive pulmonary disease	Mundipharma Research Limited	Completed	No outcome recorded
Phase 2/3	NCT00463567	Apr 2007 → Aug 2008	chronic obstructive pulmonary disease	Novartis	Completed	Met primary
Phase 3117 trials · 38 met primary · 5 missed
Phase 3	NCT07858123	Nov 2026 → Jun 2030 expected	asthma	Chiesi Farmaceutici S.p.A.	Not yet recruiting	No outcome recorded
Phase 3	NCT05735431	Jun 2026 → Nov 2027	chronic asthma	Eurofarma Laboratorios S.A.	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT06429475	Jun 2024 → Dec 2028 expected	asthma	University of KwaZulu	Recruiting	No outcome recorded
Phase 3	NCT06075095	Jan 2024 → Aug 2025	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT04233190	Apr 2023 → Oct 2024	asthma	Eurofarma Laboratorios S.A.	Completed	No outcome recorded
Phase 3	NCT05755906	Feb 2023 → Nov 2024	asthma	AstraZeneca	Completed	Met primary
Phase 3	NCT05573464	Sep 2022 → Mar 2024	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT05322707	Apr 2022 → Aug 2023	asthma	Cipla Ltd.	Completed	No outcome recorded
Phase 3	NCT05202262	Jan 2022 → Feb 2025	asthma	AstraZeneca	Completed	Met primary
Phase 3	NCT04705727	Aug → Sep 2021	childhood onset asthma	Centre Hospitalier Intercommunal Creteil	Terminated	No outcome recorded Stop: Enrollment
Show all 117 trials opens the full record — a long page
Phase 454 trials · 6 met primary · 2 missed
Phase 4	NCT06531798	Jan → Oct 2026 expected	chronic obstructive pulmonary disease	AstraZeneca	Recruiting	No outcome recorded
Phase 4	NCT07073950	Nov 2025 → May 2027 expected	chronic obstructive pulmonary disease	AstraZeneca	Recruiting	No outcome recorded
Phase 4	NCT06590740	Oct 2024 → Sep 2025	cough variant asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT05970263	Jan 2024 → Dec 2025	chronic obstructive pulmonary disease	AstraZeneca	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT06571942	Nov 2023 → Jan 2025 overdue	chronic obstructive pulmonary disease	National Institute of Respiratory Diseases, Mexico	Recruiting	No outcome recorded
Phase 4	NCT05084222	Nov 2021 → Jun 2023	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 4	NCT04671355	Oct → Dec 2021	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Withdrawn	No outcome recorded
Phase 4	NCT07809555	Aug 2021 → Nov 2024	lung disorder	Yi-Han Hsiao	Completed	No outcome recorded
Phase 4	NCT04655170	Dec 2020 → Jan 2023 overdue	chronic obstructive pulmonary disease	University of Tennessee Graduate School of Medicine	Recruiting	No outcome recorded
Phase 4	NCT04159519	Jul 2020 → Jan 2023	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT04271839	Jun 2020 → May 2021	chronic asthma	Mundipharma Pharmaceuticals S.L.	Withdrawn	No outcome recorded
Phase 4	NCT04171180	May → Sep 2020	cough variant asthma	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT03662711	Nov 2018 → Oct 2022	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Terminated	No outcome recorded
Phase 4	NCT03478696	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03563001	Jun → Sep 2018	chronic obstructive pulmonary disease	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT03551197	Jun → Sep 2018	chronic obstructive pulmonary disease	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT03028701	Sep 2015 → Mar 2017	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT02934945	Sep 2015 → Jan 2017	asthma	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT02424344	Apr 2015 → Jul 2016	chronic obstructive pulmonary disease	AstraZeneca	Completed	Missed primary
Phase 4	NCT02574975	Apr 2015 → May 2016	asthma	Zhujiang Hospital	Unknown	No outcome recorded
Phase 4	NCT04520230	Oct 2014 → Dec 2019	chronic obstructive pulmonary disease	Tanta University	Completed	No outcome recorded
Phase 4	NCT01853787	Jul 2014 → Jun 2015	chronic obstructive pulmonary disease	University of Milan	Completed	No outcome recorded
Phase 4	NCT01892787	Jul 2013 → Dec 2014	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01845025	May 2013 → May 2016	chronic asthma	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01794780	Feb 2013 → May 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01712854	Mar → Sep 2012	chronic obstructive pulmonary disease	Columbia University	Terminated	No outcome recorded
Phase 4	NCT01471340	Jan 2012 → Nov 2016	asthma	Organon and Co	Completed	No outcome recorded
Phase 4	NCT01760304	Jan → Jul 2012	chronic obstructive pulmonary disease	Brigham and Women's Hospital	Terminated	Missed primary
Phase 4	NCT01620099	Nov 2011 → Apr 2014	asthma	Università degli Studi di Ferrara	Completed	No outcome recorded
Phase 4	NCT01466712	Nov 2011 → Dec 2014	pulmonary emphysema	KU Leuven	Unknown	No outcome recorded
Phase 4	NCT01397890	Jul 2011 → Jun 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 4	NCT01344655	Apr 2011 → Sep 2012	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 4	NCT01329276	Jun → Nov 2010	chronic obstructive pulmonary disease	University Hospital, Antwerp	Completed	No outcome recorded
Phase 4	NCT00997477	Jun → Jul 2010	asthma	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT01070888	Feb 2010 → Apr 2014	exercise-induced bronchoconstriction	Boston Children's Hospital	Terminated	No outcome recorded
Phase 4	NCT00914654	Jul 2009 → Dec 2010	asthma	Bispebjerg Hospital	Unknown	No outcome recorded
Phase 4	NCT00939341	Jul 2009 → Aug 2010	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00901368	May 2009 → Sep 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 4	NCT00910793	Aug 2008 → Aug 2010	asthma	Wilfried De Backer	Completed	No outcome recorded
Phase 4	NCT00702325	Jun 2008 → Sep 2009	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00633776	Mar 2008 → Jan 2009	chronic bronchitis, pulmonary emphysema	University of California, Los Angeles	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT00546234	Nov 2007 → Jan 2014	asthma	University of Alberta	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01186653	Oct 2007 → May 2010	chronic obstructive pulmonary disease	Hull University Teaching Hospitals NHS Trust	Completed	No outcome recorded
Phase 4	NCT00489853	Jul 2007 → Aug 2008	chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary
Phase 4	NCT00561886	Apr → Oct 2007	chronic obstructive pulmonary disease	Johannes Gutenberg University Mainz	Completed	No outcome recorded
Phase 4	NCT00379028	Sep 2006 → Jul 2007	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01089322	Dec 2005 → Apr 2009	asthma	Rafael Stelmach	Completed	No outcome recorded
Phase 4	NCT00139932	Sep 2005 → Nov 2006	chronic obstructive pulmonary disease	Merck Sharp & Dohme LLC	Completed	Met primary
Phase 4	NCT00134979	Oct 2004 → Nov 2005	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Met primary
Phase 4	NCT00272753	Apr 2004 → Nov 2005	asthma	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00327353	Jan 2004 → ?	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239421	Nov 2003 → Sep 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00490243	Jul 2003 → Oct 2006	asthma	Medical University of Lodz	Completed	No outcome recorded
Phase 4	NCT00479739	Nov 2002 → Jul 2004	asthma	GlaxoSmithKline	Completed	Met primary

Phase not applicable15 trials · 1 met primary
—	NCT07595796	Jun 2026 → Feb 2028 expected	—	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Not yet recruiting	No outcome recorded
—	NCT06865040	Jul 2025 → Mar 2028 expected	—	Centre Hospitalier Universitaire, Amiens	Recruiting	No outcome recorded
—	NCT07232264	Mar → Sep 2025	asthma	Bugra Kerget	Completed	No outcome recorded
—	NCT06597682	Mar 2025 → Jul 2027 expected	long COVID-19	Huashan Hospital	Not yet recruiting	No outcome recorded
—	NCT06105671	Jan → Jul 2024	—	Morten Hostrup, PhD	Completed	No outcome recorded
—	NCT05888350	Apr 2023 → Apr 2025	—	The First Affiliated Hospital of Guangzhou Medical University	Completed	No outcome recorded
—	NCT05553184	Jul 2022 → May 2023	obesity disorder, type 2 diabetes mellitus	University of Sherbrooke	Completed	No outcome recorded
—	NCT04616261	Nov 2020 → Nov 2022	—	University of Copenhagen	Unknown	No outcome recorded
—	NCT04137029	Apr 2019 → Jul 2020	reactive airway disease	Federal State Budgetary Institution, Pulmonology Scientific Research Institute	Unknown	No outcome recorded
—	NCT03565302	Jun 2018 → May 2021	hypertrophia musculorum vera	Morten Hostrup, PhD	Unknown	No outcome recorded
—	NCT02415179	May 2015 → Feb 2016	asthma	Mahidol University	Completed	No outcome recorded
—	NCT01457716	Oct → Nov 2011	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
—	NCT01194479	Aug 2010 → Aug 2014	type 1 diabetes mellitus	Yale University	Completed	No outcome recorded
—	NCT00159263	Nov 2004 → Nov 2006	asthma	Imperial College London	Completed	Met primary
—	NCT00728715	Jan 2004 → Jan 2005	bronchiectasis	Hospital General de Requena	Completed	No outcome recorded

Comparator or background therapy144 trials
Phase 0	NCT01257048 Comparator	Aug 2011 → Jun 2012	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT06297668 Comparator	Apr → Jun 2024	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02934607 Comparator	Nov 2016 → Mar 2017	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02403713 Comparator	Aug → Oct 2014	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 1	NCT02287272 Comparator	May → Jul 2014	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Show all 144 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 33

Date	Issuer	Release
2026-09-23	AstraZeneca	Regulatory Trixeo approved in the EU for the maintenance treatment of asthma astrazeneca.com ↗ Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
2026-09-03	Chiesi Farmaceutici S.p.A.	Regulatory Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated chiesi.com ↗ Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe.
2026-07-31	Chiesi Farmaceutici S.p.A.	Regulatory Chiesi receives European Marketing Authorisation for its Single Inhaler Triple Therapy delivered via NEXThaler® for the maintenance treatment of Asthma chiesi.com ↗ The EC approval follows the positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency in May 2026.
2025-11-26	Chiesi Farmaceutici S.p.A.	Results Chiesi Advanced Carbon Minimal Inhaler (CMI) Program with New Therapeutic Equivalence Data Presented at British Thoracic Society (BTS) Winter Meeting chiesi.com ↗ The two studies presented at BTS demonstrated therapeutic equivalence and similar safety profiles of Chiesi’s beclometasone dipropionate/ formoterol fumarate product formulated with next generation HFA-152a propellant, compared to the current HFA-134a formulation, in two different strengths 1 .
2025-05-12	AstraZeneca	Regulatory Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential astrazeneca.com ↗
2025-05-02	AstraZeneca	Results Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma astrazeneca.com ↗ Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints
2022-08-24	Lupin Limited	Regulatory Lupin Receives Approval from U.S. FDA for Formoterol Fumarate Inhalation Solution lupin.com ↗
2022-03-29	Respira Therapeutics, Inc.	Results Accessorized DPI: a Shortcut Towards Flexibility and Patient Adaptability in Dry Powder Inhalation. respiratherapeutics.com ↗ Two novel findings emerged from the data collected: the aerosol quality, measured as fine particle dose, was increased by adding the accessory promoting the formulation de agglomeration and the flow dependence of the aerosol formation was reduced [1].
2022-03-16	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Regulatory Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva viatris.com ↗ The FDA final approval of Breyna, the first FDA-approved generic version of Symbicort, is an exciting milestone both for our company and the many patients living with asthma and COPD.
2021-11-01	Alembic Pharmaceuticals Ltd.	Regulatory 23rd November, 2021, Vadodara, India alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Formoterol Fumarate Inhalation Solution, 20 mcg/2 ml per Unit-Dose Vial.
2021-03-08	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Regulatory Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol viatris.com ↗ today announced that the U.S. Food and Drug Administration (FDA) granted tentative approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort ® based on an Abbreviated New Drug Application (ANDA).
2019-06-19	AstraZeneca	Regulatory Bevespi Aerosphere approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease astrazeneca.com ↗ AstraZeneca today announced that Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Japan as a fixed-dose, long-acting dual bronchodilator to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).
2018-12-20	AstraZeneca	Regulatory Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease astrazeneca.com ↗ AstraZeneca today announced that the European Commission (EC) has approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
2018-09-13	AstraZeneca	Results AstraZeneca to present Fasenra long-term safety and efficacy data at European Respiratory Society International Congress 2018 astrazeneca.com ↗ Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
2018-08-23	AstraZeneca	Results AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstructive pulmonary disease astrazeneca.com ↗ AstraZeneca today announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
2017-09-07	AstraZeneca	Results Duaklir significantly improves lung function in COPD patients astrazeneca.com ↗ These results demonstrate the improvement in lung function achieved by the combination of aclidinium and formoterol compared to single LAMA bronchodilators tiotropium and aclidinium, with comparable safety.
2017-09-07	Niox	Results Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease niox.com ↗ The AMPLIFY study met its co-primary efficacy endpoints with Duaklir® demonstrating statistically significant and clinically meaningfully improvements in lung function, measured by forced expiratory volume in one second (FEV1), compared with the combination’s individual component monotherapies (aclidinium and formoterol).
2017-05-22	Merck Sharp & Dohme LLC	Results Merck Announces Top-Line Results from the Long Term LABA Safety Study of DULERA (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol merck.com ↗ We are pleased this study met both its primary safety and key secondary efficacy endpoints,
2017-05-18	AstraZeneca	Results AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Society conference 2017 astrazeneca.com ↗
2016-09-06	GlaxoSmithKline	Results GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress gsk.com ↗ In addition, the proportion of patients who responded with the minimum clinically important difference in SGRQ (-4 units) was 50% on closed triple and 41% on budesonide/formoterol (odds ratio 1.41; p<0.001).
2016-08-30	AstraZeneca	Results AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016 astrazeneca.com ↗ A Duaklir (aclidinium/formoterol) study showing reduced deterioration in COPD compared to monotherapies and placebo (abstract #PA301)
2016-06-20	GlaxoSmithKline	Results FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients gsk.com ↗
2016-04-25	AstraZeneca	Regulatory Bevespi Aerosphere™ approved by the US FDA for patients with COPD astrazeneca.com ↗
2015-05-19	GlaxoSmithKline	Results GSK presents data at ATS on the role of blood eosinophil levels as a potential biomarker in the treatment of COPD gsk.com ↗ GSK today presented two abstracts at the American Thoracic Society (ATS) meeting that provide data on the role of blood eosinophils as a potential biomarker to determine responsiveness to treatment with an inhaled corticosteroid (ICS) in patients with COPD.
2015-03-18	AstraZeneca	Results AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD astrazeneca.com ↗ Both PT001 and PT005 also demonstrated statistically significant improvements in trough FEV1 compared to placebo.
2014-04-29	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Receives European Marketing Authorization for DuoResp Spiromax® for the Treatment of Asthma and COPD tevapharm.com ↗ Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate.
2014-04-14	Orion Corporation, Orion Pharma	Regulatory Orion receives first marketing authorisations for Bufomix Easyhaler® product orionpharma.com ↗ Orion Corporation has received Irish and Hungarian marketing authorisation for Bufomix Easyhaler®, an inhaled budesonide-formoterol combination product indicated for asthma and chronic obstructive pulmonary disease (COPD).
2014-02-21	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe tevapharm.com ↗ This CHMP decision creates a path forward for a final approval decision from the European Commission that is expected in the next few months.
2013-09-08	Boehringer Ingelheim	Results Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) prnewswire.com ↗
2013-03-21	Orion Corporation, Orion Pharma	Regulatory Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family orionpharma.com ↗ Orion Corporation has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family in Europe.
2012-02-07	Orion Corporation, Orion Pharma	Results Orion Group Financial Statement Release for 2011 orionpharma.com ↗ On 7 February Orion announced that study results received early in 2012 on a budesonide-formoterol formulation product under development for broadening the range of the Easyhaler® product family were promising, but yet insufficient for submission of an application for marketing authorisation.
2012-02-07	Orion Corporation, Orion Pharma	Results Orion continues development of inhalable budesonide-formoterol combined formulation orionpharma.com ↗ Study results received early in 2012 were promising, but yet insufficient for submission of an application for marketing authorisation.
2011-10-24	Merck Sharp & Dohme LLC	Results Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD) merck.com ↗ In Study 2, DULERA 200 mcg/10 mcg and DULERA 400 mcg/10 mcg significantly improved AM predose FEV1 at Week 13 compared to treatment with placebo, but neither dose of DULERA reached statistical significance compared to treatment with formoterol 10 mcg.

All press releases naming this drug 40 releases

Date	Issuer	Release
2026-09-23	AstraZeneca	Trixeo approved in the EU for the maintenance treatment of asthma astrazeneca.com ↗
2026-09-03	Chiesi Farmaceutici S.p.A.	Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated chiesi.com ↗
2026-07-31	Chiesi Farmaceutici S.p.A.	Chiesi receives European Marketing Authorisation for its Single Inhaler Triple Therapy delivered via NEXThaler® for the maintenance treatment of Asthma chiesi.com ↗
2025-11-26	Chiesi Farmaceutici S.p.A.	Chiesi Advanced Carbon Minimal Inhaler (CMI) Program with New Therapeutic Equivalence Data Presented at British Thoracic Society (BTS) Winter Meeting chiesi.com ↗
2025-05-12	AstraZeneca	Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential astrazeneca.com ↗
2025-05-02	AstraZeneca	Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma astrazeneca.com ↗
2024-04-18	Mundipharma Research Limited	Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered- dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint mundipharma.com ↗
2023-07-31	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva viatris.com ↗
2022-11-29	Lupin Limited	Lupin Launches Formoterol Fumarate Inhalation Solution in the United States lupin.com ↗
2022-08-24	Lupin Limited	Lupin Receives Approval from U.S. FDA for Formoterol Fumarate Inhalation Solution lupin.com ↗
2022-03-29	Respira Therapeutics, Inc.	Accessorized DPI: a Shortcut Towards Flexibility and Patient Adaptability in Dry Powder Inhalation. respiratherapeutics.com ↗
2022-03-16	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva viatris.com ↗
2021-11-01	Alembic Pharmaceuticals Ltd.	23rd November, 2021, Vadodara, India alembicpharmaceuticals.com ↗
2021-06-22	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States tevapharm.com ↗
2021-03-08	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol viatris.com ↗
2019-06-19	AstraZeneca	Bevespi Aerosphere approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease astrazeneca.com ↗
2018-12-20	AstraZeneca	Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease astrazeneca.com ↗
2018-09-13	AstraZeneca	AstraZeneca to present Fasenra long-term safety and efficacy data at European Respiratory Society International Congress 2018 astrazeneca.com ↗
2018-08-23	AstraZeneca	AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstructive pulmonary disease astrazeneca.com ↗
2017-09-07	AstraZeneca	Duaklir significantly improves lung function in COPD patients astrazeneca.com ↗
2017-09-07	Niox	Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease niox.com ↗
2017-05-22	Merck Sharp & Dohme LLC	Merck Announces Top-Line Results from the Long Term LABA Safety Study of DULERA (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol merck.com ↗
2017-05-18	AstraZeneca	AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Society conference 2017 astrazeneca.com ↗
2016-09-06	GlaxoSmithKline	GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress gsk.com ↗
2016-09-02	Orion Corporation, Orion Pharma	Orion Corporation and Menarini Group collaborate on budesonide-formoterol Easyhaler® combination product for asthma and COPD orionpharma.com ↗
2016-09-02	Menarini Group	Orion Corporation and Menarini Group collaborate on budesonide-formoterol Easyhaler® combination product for asthma and COPD menarini.com ↗
2016-08-30	AstraZeneca	AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016 astrazeneca.com ↗
2016-06-20	GlaxoSmithKline	FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients gsk.com ↗
2016-04-25	AstraZeneca	Bevespi Aerosphere™ approved by the US FDA for patients with COPD astrazeneca.com ↗
2015-05-19	GlaxoSmithKline	GSK presents data at ATS on the role of blood eosinophil levels as a potential biomarker in the treatment of COPD gsk.com ↗
2015-03-18	AstraZeneca	AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD astrazeneca.com ↗
2014-04-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives European Marketing Authorization for DuoResp Spiromax® for the Treatment of Asthma and COPD tevapharm.com ↗
2014-04-14	Orion Corporation, Orion Pharma	Orion receives first marketing authorisations for Bufomix Easyhaler® product orionpharma.com ↗
2014-02-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe tevapharm.com ↗
2013-09-08	Boehringer Ingelheim	Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) prnewswire.com ↗
2013-03-21	Orion Corporation, Orion Pharma	Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family orionpharma.com ↗
2012-11-30	Orion Corporation, Orion Pharma	Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family orionpharma.com ↗
2012-02-07	Orion Corporation, Orion Pharma	Orion Group Financial Statement Release for 2011 orionpharma.com ↗
2012-02-07	Orion Corporation, Orion Pharma	Orion continues development of inhalable budesonide-formoterol combined formulation orionpharma.com ↗
2011-10-24	Merck Sharp & Dohme LLC	Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD) merck.com ↗

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 425 sources stand behind the page.

Field	Value	Cited text
Known as	formoterol	“This study investigated the efficacy and tolerability of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol)*, administered...” PMID 23870606 ↗ Jul 2013 282 “participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid...” NCT06272370 ↗ “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “In the first study period (Period 1), patients with moderate to severe persistent asthma according to GINA criteria, with or without COPD, will be randomized at a 1: 1 ratio to...” NCT04233190 ↗ “Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg in Patients With Stable Asthma Using Bronchoprovocation With Methacholine as a Bioassay...” NCT01256086 ↗ “This study was conducted to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) administered through metered-dose inhaler (MDI) in patients with persistent...” PMID 20874458 ↗ Nov 2010 “A U.S., multicenter, five-way crossover study compared single doses of formoterol, a long-acting beta-agonist, via pMDI (2.25, 4.5, and 9 micrograms) or dry powder inhaler (12...” PMID 24717790 ↗ Mar 2014 “160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25...” NCT02631941 ↗ “160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25...” NCT02237508 ↗ “Primary objectives were to assess total systemic exposure (without charcoal) and lung exposure (with charcoal) of budesonide, glycopyrronium, and formoterol administered as BGF...” PMID 32253054 ↗ Apr 2020 “We evaluated the effects of the long acting bronchodilator components of the extrafine single inhaler triple therapy beclometasone dipropionate/formoterol/glycopyrronium...” PMID 33298062 ↗ Dec 2020 Show 272 more sources
Known as	Atimos	“Thus, the primary objective for the present study is to compare the two extremes of available long acting beta-agonist formulations - i.e. extra fine HFA formoterol ( Atimos )...” NCT01892787 ↗ 2 “BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)” NCT01803087 ↗ “Formoterol 12 μg pMDI (Atimos®)” NCT01344655 ↗
Known as	CHF 1531	“different doses of CHF 1531 pressurized metered dose inhaler (pMDI) containing formoterol fumarate” NCT03086460 ↗
Known as	F12D	“Formoterol fumarate 12 μg DPI (F12D)” NCT00746330 ↗
Known as	F12M	“Formoterol fumarate 12 μg pMDI (F12M)” NCT00746330 ↗
Known as	FF	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898984 ↗
Known as	FF MDI	“Patients received GFF MDI 18/9.6 μg, glycopyrrolate (GP) MDI 18 μg, formoterol fumarate (FF) MDI 9.6 μg, or placebo MDI, twice-daily for 24 weeks.” PMID 32450869 ↗ May 2020 1 “Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)” NCT02343458 ↗
Known as	FFIS	“nebulized formoterol fumarate inhalation solution (Perforomist**, FFIS 20g BID)” PMID 19232039 ↗ Mar 2009
Known as	FOR	“twice-daily inhaled corticosteroid/long-acting β2-agonist therapy [budesonide/formoterol (BUD/FOR)] 400 µg/12 µg in patients with symptomatic COPD at risk of exacerbations” PMID 29313286 ↗ Jan 2018 2 “extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID, vs. FOR 12 μg pMDI, 1 inhalation BID” PMID 24953015 ↗ Jun 2014 “formoterol fumarate 12 microg twice-daily (FOR) plus TIO 18 microg once-daily” PMID 20580216 ↗ Jun 2010
Known as	Foradil	“FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler.” NCT01108627 ↗ 10 “plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.” NCT00801684 ↗ “fluticasone plus formoterol (Flixotide Evohaler, pMDI, Flovent [HFA]; Foradil, DPI, Foradil Aerolizer) administered concurrently” PMID 23368897 ↗ Feb 2013 “long acting bronchodilators "foradil/spiriva" or combined LABD and inhaled steroids” NCT02257463 ↗ “Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.” NCT00460577 ↗ “Foradil inh kap 12 mcg/dosage, 60 caps” NCT00628758 ↗ NCT06282861 ↗ NCT00931385 ↗ NCT00734318 ↗ NCT00932646 ↗ NCT01108627 ↗
Known as	Foradil (aerosolizer dry powder formoterol fumarate)	“Foradil (aerosolizer dry powder formoterol fumarate)” NCT00633776 ↗
Known as	Foradil Aerolizer	“FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler.” NCT01108627 ↗ 6 “received nebulized formoterol fumarate (Perforomist inhalation solution; FFIS 20 microg) or DPI (Foradil Aerolizer; FA 12 microg), or placebo twice daily for 12 weeks.” PMID 18363201 ↗ Feb 2008 “fluticasone plus formoterol (Flixotide Evohaler, pMDI, Flovent [HFA]; Foradil, DPI, Foradil Aerolizer) administered concurrently” PMID 23368897 ↗ Feb 2013 “1 or 2 doses of formoterol, (Foradil Aerolizer 12 mcg/capsule) a long-acting bronchodilator” NCT00643578 ↗ “Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)” NCT00830102 ↗ “Drug: Formoterol Fumarate 12 mcg (Foradil Aerolizer)” NCT06865040 ↗ “Formoterol Fumarate 12 μg (Foradil® Aerolizer®)” NCT01085045 ↗
Known as	Form	“The participants were then randomized to budesonide/formoterol (Bud + Form; 400/12 μg BID), fluticasone/salmeterol (Flu + Salm; 250/50 μg BID), or formoterol only (12 μg BID)...” PMID 34464242 ↗ Nov 2021 1 “Many studies have shown the superior efficacy of budesonide (BUD)/formoterol (FORM) maintenance and reliever therapy, but still lack evidence of its efficacy in Chinese asthma patients” PMID 22932169 ↗ Sep 2012
Known as	formoterol (fumarate dihydrate)	“GFF MDI is a long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a...” PMID 30218695 ↗ Sep 2018 5 “Extrafine beclomethasone dipropionate 100 mcg/formoterol fumarate dihydrate 6 mcg (Foster®), 1 inhalation twice daily for 4 weeks, plus salbutamol 100 mcg as needed (max 200...” NCT07809555 ↗ “formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler” NCT03846570 ↗ “Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.” NCT03788395 ↗ NCT03015259 ↗ NCT05322707 ↗
Known as	Formoterol (Pressair)	“Formoterol (Pressair®)” NCT02796651 ↗
Known as	formoterol fumarate	“BACKGROUND: This study evaluated the lung deposition and the distribution pattern in the airways of a fixed combination of beclometasone dipropionate (BDP) and formoterol...” PMID 29989511 ↗ Jul 2018 143 “The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related...” NCT01845025 ↗ “Glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA), glycopyrrolate (GP), and the...” PMID 29567116 ↗ Feb 2018 “Eligible participants were randomized 1:1 to receive either extrafine beclomethasone dipropionate/formoterol fumarate (100 mcg/6 mcg, 1 puff twice daily) plus as-needed...” NCT07809555 ↗ “An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some...” PMID 28065679 ↗ Jan 2017 “Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total...” NCT00747318 ↗ “The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a...” PMID 21605396 ↗ May 2011 “The purpose of this study is to evaluate the safety and efficacy of inhaled formoterol fumarate (7.2 and 9.6 µg ex-actuator) compared to placebo and Foradil Aerolizer in...” NCT01043601 ↗ “Foster is a combination therapy containing beclometasone dipropionate (an inhaled corticosteroid, or ICS) and formoterol fumarate (a long-acting beta-agonist, or LABA), which...” NCT06869382 ↗ “formoterol fumarate, a long-acting β2-AR agonist given four hours following injury, when glomerular dysfunction is already established, restored glomerular structure,...” NCT07022418 ↗ “BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9...” NCT06110403 ↗ Show 133 more sources
Known as	formoterol fumarate dehydrate	“SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)” NCT02062463 ↗ 1 “Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg” NCT06531798 ↗
Known as	Formoterol Fumarate Inhalation Aerosol	“Formoterol Fumarate Inhalation Aerosol” NCT02766608 ↗
Known as	formoterol fumarate metered dose inhaler (FF MDI)	“formoterol fumarate metered dose inhaler (FF MDI)” NCT01854658 ↗
Known as	Formoterol Furamate	“The Investigational Medicinal Product (IMP) consists of a combination of Budesonide (corticosteroid) and Formoterol Furamate (fast-acting β2 agonist) dihydrate.” NCT06429475 ↗
Known as	FORMOTEROL VIATRIS	“FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®)” NCT06865040 ↗
Known as	Oxeze	“Oxeze” NCT00546234 ↗
Known as	Oxis	“Oxis turbuhaler 4.5-9 mcg/dosage, 60 dosage” NCT00628758 ↗ 1 NCT06282861 ↗
Known as	Oxis Turbuhaler	“Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations.” NCT01836016 ↗ 2 “Oral Prednisolone + Formoterol (Oxis® Turbuhaler) During Two Weeks” NCT00259779 ↗ “Formoterol Alone (Oxis® Turbuhaler® 4.5 µg)” NCT00288379 ↗
Known as	Perforomist	“Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution” NCT03573817 ↗ 2 “nebulized formoterol fumarate inhalation solution (Perforomist**, FFIS 20g BID)” PMID 19232039 ↗ Mar 2009 “Revefenacin (YUPELRI) & Formoterol (Perforomist)” NCT04655170 ↗
Known as	Perforomist (nebulized formoterol fumarate)	“Perforomist (nebulized formoterol fumarate)” NCT00633776 ↗
Known as	Perforomist inhalation solution	“received nebulized formoterol fumarate (Perforomist inhalation solution; FFIS 20 microg) or DPI (Foradil Aerolizer; FA 12 microg), or placebo twice daily for 12 weeks.” PMID 18363201 ↗ Feb 2008
Known as	PT005	“Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)” NCT02343458 ↗ 3 “Budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009)” NCT02196077 ↗ “Formoterol Fumarate MDI (PT005; 7.2 and 9.6 µg Ex-actuator)” NCT01043601 ↗ “FF MDI (PT005)” NCT01970878 ↗
Action	Activate	“long-acting β(2)-adrenergic agonists” PMID 22383665 ↗ Aug 2012
Modality	Other / unclassified	“long-acting β(2)-adrenergic agonists” PMID 22383665 ↗ Aug 2012
Route	Inhaled	“Formoterol Inhalant Powder” NCT00159263 ↗